4.3 Article

The INSPIRE study: Do personality traits predict general quality of life (Short form-36) in distressed patients with ulcerative colitis and Crohn's disease?

Journal

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
Volume 43, Issue 12, Pages 1505-1513

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/00365520802321196

Keywords

Crohn's disease; inflammatory bowel disease; personality; quality of life; short form 36; ulcerative colitis

Funding

  1. Norwegian Research Council [160044/v50]
  2. Helse-Soer [3b-111]

Ask authors/readers for more resources

Objective. To assess the role of personality as a predictor of Short form-36 (SF-36) in distressed patients (perceived stress questionnaire, PSQ) with ulcerative colitis (UC) and Crohn's disease (CD). Material and methods. Fifty-four patients with CD and 55 with UC (age 18-60 years) who had relapsed in the previous 18 months, i.e. with an activity index (AI) for UC or CD4, PSQ60, and without severe mental or other major medical conditions, completed the Buss-Perry Aggression Questionnaire (BPA), the Neuroticism and Lie scales of the Eysenck Personality Questionnaire (EPQ-N and -L), the Multidimensional Health Locus of Control Scale (LOC) (Internal (I), Powerful Other (PO), Chance (C)), the Toronto Alexithymia Scale (TAS) and the SF-36. Results. Multiple linear regression analyses controlling for gender, age and clinical disease activity (AI) in separate analyses for UC and CD showed that the mental and vitality subscales were predicted by neuroticism in both UC and CD. The highest explained variance was 43.8% on the mental subscale in UC. The social function subscale was related to alexithymia only in UC, while the role limitation and pain subscales were related to personality in CD only. The physical function subscale related differently to personality in UC and CD. Conclusions. While mental and vitality subscales were predicted by neuroticism in both UC and CD, other subscales had different relationships to personality, suggesting different psychobiological interactions in UC and CD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Meeting Abstract Oncology

Presurgical treatment with ribociclib and letrozole in patients with locally advanced breast cancer: The NEOLETRIB study

Xavier Tekpli, Shom Goel, Barbro Holm, Lars-Egil Fallang, Laurens Cornelus Reitsma, Stephanie Beate Geisler, Hilde Presterud Odegard, Cathrine Bergquist Fosskaug, Ida Caroline Lindem, Manouchehr Seyedzadeh, Jonn Terje Geitung, Joana Reis, Kjell Inge Gjesdal, Unn-Cathrin Buvarp, Marie Loeng, Kristine Kleivi Sahlberg, Alina Carmen Porojnicu, Helle Kristine Skjerven, Andliena Tahiri, Shakila Jabeen, Torben Luders, Vahid Bemanian, Jorgen Jahnsen, Marianne Lyngra, Antoni Hurtado, Jason Carroll, Shiuan Chen, Vessela Kristensen, Jurgen Geisler

CANCER RESEARCH (2022)

Letter Medicine, General & Internal

Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases Reply

SiljeWatterdal Syversen, Jorgen Jahnsen, Espen A. Haavardsholm

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Article Gastroenterology & Hepatology

Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2

Jan K. Nowak, Alex T. Adams, Rahul Kalla, Jonas C. Lindstrom, Simen Vatn, Daniel Bergemalm, Asa Keita, Fernando Gomollon, Jorgen Jahnsen, Morten H. Vatn, Petr Ricanek, Jerzy Ostrowski, Jaroslaw Walkowiak, Jonas Halfvarson, Jack Satsangi

Summary: This study uses whole-blood transcriptomic analysis to investigate the pathobiology of inflammatory bowel disease (IBD) and its potential translational implications.

JOURNAL OF CROHNS & COLITIS (2022)

Article Medicine, General & Internal

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial

Marthe Kirkesaether Brun, Guro Lovik Goll, Kristin Kaasen Jorgensen, Joseph Sexton, Johanna Elin Gehin, Oystein Sandanger, Inge Christoffer Olsen, Rolf Anton Klaasen, David John Warren, Cato Mork, Tore K. Kvien, Jorgen Jahnsen, Nils Bolstad, Espen A. Haavardsholm, Silje Watterdal Syversen

Summary: This study identified several risk factors for the formation of anti-drug antibodies (ADAb) during early-phase infliximab treatment. Factors such as a diagnosis of rheumatoid arthritis, lifetime smoking, concomitant immunosuppressors, and a diagnosis of spondyloarthritis were associated with increased or reduced risk of ADAb formation. Additionally, higher disease activity and longer drug holidays increased the risk, while higher doses and serum concentrations of infliximab reduced the risk of immunogenicity.

JOURNAL OF INTERNAL MEDICINE (2022)

Article Rheumatology

Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy

Silje W. Syversen, Ingrid Jyssum, Anne T. Tveter, Trung T. Tran, Joseph Sexton, Sella A. Provan, Siri Mjaaland, David J. Warren, Tore K. Kvien, Gunnveig Grodeland, Lise S. H. Nissen-Meyer, Petr Ricanek, Adity Chopra, Ane M. Andersson, Grete B. Kro, Jorgen Jahnsen, Ludvig A. Munthe, Espen A. Haavardsholm, John T. Vaage, Fridtjof Lund-Johansen, Kristin K. Jorgensen, Guro L. Goll

Summary: This study evaluated the immunogenicity and safety of the standard SARS-CoV-2 vaccination regimen and a third dose in patients with immune-mediated inflammatory diseases (IMIDs) receiving immunosuppressive therapy. The results showed that IMID patients had a weaker response to the standard vaccine regimen, but the serologic response improved after receiving a third dose. These data help identify IMID patients who may benefit from a third vaccine dose.

ARTHRITIS & RHEUMATOLOGY (2022)

Review Gastroenterology & Hepatology

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Jordi Guardiola, Jorgen Jahnsen, Charles Lees, Edouard Louis, Milan Lukas, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun, Dong-Hyeon Kim, Sung Jeong Lee, Raja Atreya

Summary: This study compared the efficacy and safety of infliximab and vedolizumab in adult patients with moderate-to-severe Crohn's disease or ulcerative colitis. The results showed that infliximab had better efficacy during the induction phase and comparable efficacy during the maintenance phase compared to vedolizumab. In terms of safety, there were no significant differences between the two treatments.

BMC GASTROENTEROLOGY (2022)

Article Gastroenterology & Hepatology

Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

Kristin H. Bjorlykke, Jorgen Jahnsen, Jorn Brynskov, Pauliina Molander, Michael Eberhardson, Loa G. Davidsdottir, Taina Sipponen, Henrik Hjortswang, Guro Lovik Goll, Silje Watterdal Syversen, Ebbe Langholz, Kristin K. Jorgensen, Casper Steenholdt

Summary: Therapeutic drug monitoring (TDM) is widely implemented and utilized in Scandinavia to optimize biologic and thiopurine therapies in inflammatory bowel disease (IBD). However, the lack of guidelines and delayed test response time are the main barriers to the use of TDM.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2023)

Article Multidisciplinary Sciences

Single cell transcriptomic analysis of the immune cell compartment in the human small intestine and in Celiac disease

Nader Atlasy, Anna Bujko, Espen S. Baekkevold, Peter Brazda, Eva Janssen-Megens, Knut E. A. Lundin, Jorgen Jahnsen, Frode L. Jahnsen, Hendrik G. Stunnenberg

Summary: This study characterizes the immune cell compartment of the human small intestine during active Celiac disease using single cell transcriptomics. The results show altered myeloid cell transcriptomes and extensive changes in CD4(+) and CD8(+) T cell transcriptomes. In addition, a reduced population of natural intraepithelial lymphocytes is observed in Celiac disease.

NATURE COMMUNICATIONS (2022)

Meeting Abstract Gastroenterology & Hepatology

Work disability after 20 years with Inflammatory Bowel Disease - results from the IBSEN study

C. Lund, V. A. Kristensen, I. L. Monstad, I. C. Solberg, O. Hovde, G. Huppertz-Hauss, M. Henriksen, O. Hoie, T. Bernklev, J. Jahnsen, B. Moum, M. L. Hoivik

JOURNAL OF CROHNS & COLITIS (2022)

Meeting Abstract Gastroenterology & Hepatology

Work disability after 20 years with Inflammatory Bowel Disease - results from the IBSEN study

C. Lund, V. A. Kristensen, I. L. Monstad, I. C. Solberg, O. Hovde, G. Huppertz-Hauss, M. Henriksen, O. Hoie, T. Bernklev, J. Jahnsen, B. Moum, M. L. Hoivik

JOURNAL OF CROHNS & COLITIS (2022)

Meeting Abstract Gastroenterology & Hepatology

Genetic predisposition to infliximab immunogenicity in patients with immune-mediated inflammatory diseases - secondary analyses from a randomised clinical trial

K. Bjorlykke, M. K. Brun, M. K. Viken, G. E. Stenvik, R. A. Klaasen, J. E. Gehin, D. J. Warren, J. Sexton, E. A. Haavardsholm, J. Jahnsen, B. A. Lie, G. L. Goll, N. Bolstad, S. W. Syversen, K. K. Jorgensen

JOURNAL OF CROHNS & COLITIS (2022)

Meeting Abstract Gastroenterology & Hepatology

Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice

K. Bjorlykke, J. Jahnsen, J. Brynskov, P. Molander, M. Eberhardson, L. G. Davidsdottir, T. Sipponen, H. Hjortswang, E. Langholz, K. K. Jorgensen, C. Steenholdt

JOURNAL OF CROHNS & COLITIS (2022)

Meeting Abstract Gastroenterology & Hepatology

Genetic predisposition to infliximab immunogenicity in patients with immune-mediated inflammatory diseases - secondary analyses from a randomised clinical trial

K. Bjorlykke, M. K. Brun, M. K. Viken, G. E. Stenvik, R. A. Klaasen, J. E. Gehin, D. J. Warren, J. Sexton, E. A. Haavardsholm, J. Jahnsen, B. A. Lie, G. L. Goll, N. Bolstad, S. W. Syversen, K. K. Jorgensen

JOURNAL OF CROHNS & COLITIS (2022)

Meeting Abstract Gastroenterology & Hepatology

Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice

K. Bjorlykke, J. Jahnsen, J. Brynskov, P. Molander, M. Eberhardson, L. G. Davidsdottir, T. Sipponen, H. Hjortswang, E. Langholz, K. K. Jorgensen, C. Steenholdt

JOURNAL OF CROHNS & COLITIS (2022)

Meeting Abstract Gastroenterology & Hepatology

Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study

K. K. Jorgensen, S. W. Syversen, I. Jyssum, A. T. Tveter, T. T. Tran, J. Sexton, S. A. Provan, S. Mjaaland, D. J. Warren, T. K. Kvien, G. Grodeland, L. S. Nissen-Meyer, P. Ricanek, A. Chopra, A. M. Andersson, G. B. Kro, J. Jahnsen, L. A. Munthe, E. A. Haavardsholm, J. T. Vaage, F. Lund-Johansen, G. L. Goll

JOURNAL OF CROHNS & COLITIS (2022)

No Data Available